USA flag logo/image

An Official Website of the United States Government

SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
 Program Year/Program:
2011 / SBIR
Agency Tracking Number:
N43CO110077 		Solicitation Year:
2011 		Solicitation Topic Code:
NCI 		Solicitation Number:
Small Business Information
BIOTEX, INC.
8058 EL RIO ST HOUSTON, TX 77054-4104
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: SBIR TOPIC 294 PHASE 1 - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH
Agency: HHS
Contract: N43CO110077
Award Amount: $149,919.00
 

Abstract:

The carbohydrate modification O-GlcNAc is nearly as abundant as protein phosphorylation in proteins, competes with it, and has extensive crosstalk to regulate signaling, transcription, and the functions of oncogenes and tumor suppressors. However, analysisof protein O-GlcNAcylation currently requires difficult and time-consuming methods such as sophisticated mass spectrometry. There is a need to develop new reagents and simpler methods to study the function of carbohydrate modifications (O-linked and N-linked) of proteins in cancer biology. Even in labs with the ability to make glycosylation-specific antibodies, it is simply too time-consuming and expensive to do that on a scale which would have an impact on the field. DNA aptamers, on the other hand, arereadily synthesized and at least 10 times less expensive than antibodies. This project utilizes a new tool, parallel selection of DNA aptamers to rapidly identify high-affinity ligands to tens or even hundreds of glycoprotein or modified polypeptide targets simultaneously. In this NIH Phase I SBIR project, we will demonstrate the utility of our tool for selecting aptamers to numerous important glycoproteins implicated in cancer biology. We will also develop high affinity reagents to specific glycopeptides which are likely to find enormous utility in the understanding of cancer glycobiology.

Principal Investigator:

George W. Jackson
713-741-0111
BILL@BIOTEXMEDICAL.COM

Business Contact:

George W. Jackson
713-741-0111
BILL@BIOTEXMEDICAL.COM
Small Business Information at Submission:

BIOTEX, INC.
8058 EL RIO ST. HOUSTON, TX 77054-4104

EIN/Tax ID: 742824041
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No